

Electronic Supplementary Information (ESI)

of

Carrier free photodynamic oxidizer for enhanced tumor therapy by redox homeostasis disruption

Ni Yang,[†] Rongrong Zheng,[†] Ziying Chen, Ruixin Wang, Linping Zhao, Xiayun Chen,

*Lei Chen, Lin Xu, * Shiyong Li* and Ali Chen**




Fig. S1. Standard curves of (A) Nap and (B) Pyro by using HPLC and UV-vis spectrum.




Fig. S2. Drug release curve of Pyro by detecting the fluorescence of released Pyro at scheduled time (n=2).




Fig. S3. Flow cytometry analysis of 4T1 cells after treatment with Pyro or PyroNap for 1, 3 and 6 h (n=3).




Fig. S4. The quantitative analysis of DCF fluorescence in 4T1 cells after treatment with Nap, Pyro, PyroNap in the presence or absence of light. **P < 0.01 and ***P < 0.001 were tested *via* a student's t-test (n=3).




Fig. S5. The quantitative analysis of PI fluorescence in 4T1 cells after treatment with Nap, Pyro, PyroNap in the absence or presence of light. **P < 0.01 and ***P < 0.001 were tested *via* a student's t-test (n=3).




Fig. S6. The quantitative analysis of TUNEL immunofluorescence in 4T1 tumor tissues after treatment with Nap, Pyro, PyroNap in the absence or presence of light on the 14th day. ***P < 0.001 was tested *via* a student's t-test (n=3).